{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:44:05Z","timestamp":1789559045602,"version":"build-2803163510"},"reference-count":37,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,1,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Although recent advances in molecular genetics have enabled improved risk classification of follicular lymphoma (FL) using, for example, the m7-FLIPI score, the impact on treatment has been limited. We aimed to assess the prognostic significance of copy-number aberrations (CNAs) and copy-neutral loss of heterozygosity (cnLOH) identified by chromosome genomic-array testing (CGAT) at FL diagnosis using prospectively collected clinical trial specimens from 255 patients enrolled in the SWOG study S0016. The impact of genomic aberrations was assessed for early progression (progressed or died within 2 years after registration), progression-free survival (PFS), and overall survival (OS). We showed that increased genomic complexity (ie, the total number of aberration calls) was associated with poor outcome in FL. Certain chromosome arms were critical for clinical outcome. Prognostic CNAs\/cnLOH were identified: whereas early progression was correlated with 2p gain (P = .007; odds ratio [OR] = 2.55 [1.29, 5.03]) and 2p cnLOH (P = .005; OR = 10.9 [2.08, 57.2]), 2p gain specifically encompassing VRK2 and FANCL predicted PFS (P = .01; hazard ratio = 1.80 [1.14, 2.68]) as well as OS (P = .005; 2.40 [1.30, 4.40]); CDKN2A\/B (9p) deletion correlated with worse PFS (P = .004, 3.50 [1.51, 8.28]); whereas CREBBP (16p) (P &amp;lt; .001; 6.70 [2.52, 17.58]) and TP53 (17p) (P &amp;lt; .001; 3.90 [1.85, 8.31]) deletion predicted worse OS. An independent cohort from the m7-FLIPI study was explored, and the prognostic significance of aberration count, and TP53 and CDKN2A\/B deletion were further validated. In conclusion, assessing genomic aberrations at FL diagnosis with CGAT improves risk stratification independent of known clinical parameters, and provides a framework for development of future rational targeted therapies.<\/jats:p>","DOI":"10.1182\/blood-2018-07-865428","type":"journal-article","created":{"date-parts":[[2018,11,19]],"date-time":"2018-11-19T05:44:26Z","timestamp":1542606266000},"page":"81-93","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":55,"title":["Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016"],"prefix":"10.1182","volume":"133","author":[{"given":"Xiaoyu","family":"Qu","sequence":"first","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongli","family":"Li","sequence":"additional","affiliation":[{"name":"SWOG Statistical Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita M.","family":"Braziel","sequence":"additional","affiliation":[{"name":"Department of Pathology, Oregon Health & Science University, Portland, OR;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Passerini","sequence":"additional","affiliation":[{"name":"Department of Medicine III, University Hospital, Ludwig Maximilians University Munich, Munich, Germany;"},{"name":"German Cancer Consortium, German Cancer Research Center, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Rimsza","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Scottsdale, AZ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Hsi","sequence":"additional","affiliation":[{"name":"Cleveland Clinic, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Leonard","sequence":"additional","affiliation":[{"name":"Weill Cornell Medicine\/New York Presbyterian Hospital, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali M.","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Chicago, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Kridel","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, University Health Network (UHN), Toronto, ON, Canada; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3147-8037","authenticated-orcid":false,"given":"Oliver","family":"Press","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Weigert","sequence":"additional","affiliation":[{"name":"Department of Medicine III, University Hospital, Ludwig Maximilians University Munich, Munich, Germany;"},{"name":"German Cancer Consortium, German Cancer Research Center, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"LeBlanc","sequence":"additional","affiliation":[{"name":"SWOG Statistical Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Friedberg","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Rochester, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Fang","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"7","key":"2020021109364806300_B1","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1200\/JCO.2017.74.5083","article-title":"Continued excellent outcomes in previously untreated patients with follicular lymphoma after treatment with CHOP plus rituximab or CHOP plus 131I-tositumomab: long-term follow-up of phase III randomized study SWOG-S0016","volume":"36","author":"Shadman","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"2020021109364806300_B2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.beha.2017.11.002","article-title":"Risk stratification in follicular lymphoma","volume":"31","author":"Casulo","year":"2018","journal-title":"Best Pract Res Clin Haematol"},{"issue":"23","key":"2020021109364806300_B3","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"11","key":"2020021109364806300_B4","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/ajh.24492","article-title":"Early event status informs subsequent outcome in newly diagnosed follicular lymphoma","volume":"91","author":"Maurer","year":"2016","journal-title":"Am J Hematol"},{"issue":"8","key":"2020021109364806300_B5","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood-2016-05-717355","article-title":"Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy","volume":"128","author":"Jurinovic","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2020021109364806300_B6","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular Lymphoma International Prognostic Index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"issue":"27","key":"2020021109364806300_B7","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular Lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"issue":"35","key":"2020021109364806300_B8","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1200\/JCO.2012.43.0934","article-title":"Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte and GOELAMS","volume":"30","author":"Dupuis","year":"2012","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2020021109364806300_B9","first-page":"413","article-title":"Discovery and validation of a simplified scoring system (the PRIMA-Prognostic Index) in de novo follicular lymphoma treated initially with immunochemotherapy [abstract]","volume":"130","author":"Bachy","year":"2017","journal-title":"Blood"},{"issue":"9","key":"2020021109364806300_B10","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"2020021109364806300_B11","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1470-2045(18)30102-5","article-title":"A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts","volume":"19","author":"Huet","year":"2018","journal-title":"Lancet Oncol"},{"issue":"2","key":"2020021109364806300_B12","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00277-017-3154-z","article-title":"Current prognostic and predictive factors in follicular lymphoma","volume":"97","author":"Sorigue","year":"2018","journal-title":"Ann Hematol"},{"issue":"23","key":"2020021109364806300_B13","doi-asserted-by":"crossref","first-page":"6624","DOI":"10.1158\/1078-0432.CCR-13-1120","article-title":"A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine\u2013tositumomab","volume":"19","author":"Press","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2020021109364806300_B14","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.3324\/haematol.2017.175059","article-title":"Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort","volume":"103","author":"Rimsza","year":"2018","journal-title":"Haematologica"},{"issue":"3","key":"2020021109364806300_B15","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1200\/JCO.2012.42.4101","article-title":"Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016","volume":"31","author":"Press","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"2020021109364806300_B16","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.ccr.2012.07.014","article-title":"Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma","volume":"22","author":"Monti","year":"2012","journal-title":"Cancer Cell"},{"issue":"4","key":"2020021109364806300_B17","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3109\/10428194.2015.1080364","article-title":"Cross-platform assessment of genomic imbalance confirms the clinical relevance of genomic complexity and reveals loci with potential pathogenic roles in diffuse large B-cell lymphoma","volume":"57","author":"Dias","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"2020021109364806300_B18","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/gcc.22184","article-title":"Amplification of 2p as a genomic marker for transformation in lymphoma","volume":"53","author":"Kwiecinska","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"issue":"7337","key":"2020021109364806300_B19","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature09730","article-title":"Inactivating mutations of acetyltransferase genes in B-cell lymphoma","volume":"471","author":"Pasqualucci","year":"2011","journal-title":"Nature"},{"issue":"2","key":"2020021109364806300_B20","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.cancergencyto.2009.02.020","article-title":"Gain of chromosome arm 1q in patients in relapse and progression of multiple myeloma","volume":"192","author":"Balc\u00e1rkov\u00e1","year":"2009","journal-title":"Cancer Genet Cytogenet"},{"issue":"21","key":"2020021109364806300_B21","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/cncr.28239","article-title":"Gain of 1q is associated with inferior event-free and overall survival in patients with favorable histology Wilms tumor: a report from the Children\u2019s Oncology Group","volume":"119","author":"Gratias","year":"2013","journal-title":"Cancer"},{"issue":"7","key":"2020021109364806300_B22","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1200\/JCO.2008.16.0630","article-title":"Overall genomic pattern is a predictor of outcome in neuroblastoma","volume":"27","author":"Janoueix-Lerosey","year":"2009","journal-title":"J Clin Oncol"},{"issue":"12","key":"2020021109364806300_B23","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1002\/gcc.20496","article-title":"ArrayCGH-based classification of neuroblastoma into genomic subgroups","volume":"46","author":"Michels","year":"2007","journal-title":"Genes Chromosomes Cancer"},{"issue":"34","key":"2020021109364806300_B24","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1200\/JCO.2012.48.4923","article-title":"Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load","volume":"31","author":"Neben","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4","key":"2020021109364806300_B25","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2016-07-729954","article-title":"Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma","volume":"129","author":"Krysiak","year":"2017","journal-title":"Blood"},{"issue":"8","key":"2020021109364806300_B26","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2002-07-2119","article-title":"Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations","volume":"101","author":"Martinez-Climent","year":"2003","journal-title":"Blood"},{"issue":"12","key":"2020021109364806300_B27","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1182\/blood.V98.12.3413","article-title":"The BCL11 gene family: involvement of BCL11A in lymphoid malignancies","volume":"98","author":"Satterwhite","year":"2001","journal-title":"Blood"},{"issue":"23","key":"2020021109364806300_B28","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1182\/blood-2012-11-465138","article-title":"Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations","volume":"121","author":"Neumann","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2020021109364806300_B29","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/ni767","article-title":"TOX: an HMG box protein implicated in the regulation of thymocyte selection","volume":"3","author":"Wilkinson","year":"2002","journal-title":"Nat Immunol"},{"issue":"10","key":"2020021109364806300_B30","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1038\/modpathol.2017.58","article-title":"Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms","volume":"30","author":"Onaindia","year":"2017","journal-title":"Mod Pathol"},{"issue":"5","key":"2020021109364806300_B31","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/s41375-018-0043-y","article-title":"Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma","volume":"32","author":"Araf","year":"2018","journal-title":"Leukemia"},{"issue":"6","key":"2020021109364806300_B32","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1182\/blood-2016-05-718494","article-title":"Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling","volume":"129","author":"Myklebust","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2020021109364806300_B33","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/gcc.20617","article-title":"Microarray-based genomic profiling reveals novel genomic aberrations in follicular lymphoma which associate with patient survival and gene expression status","volume":"48","author":"Schwaenen","year":"2009","journal-title":"Genes Chromosomes Cancer"},{"issue":"6","key":"2020021109364806300_B34","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1182\/blood-2017-08-737361","article-title":"Chromatin modifying gene mutations in follicular lymphoma","volume":"131","author":"Green","year":"2018","journal-title":"Blood"},{"issue":"5","key":"2020021109364806300_B35","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1200\/JCO.2016.70.8651","article-title":"Thirty-month complete response as a surrogate end point in first-line follicular lymphoma therapy: an individual patient-level analysis of multiple randomized trials","volume":"35","author":"Shi","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10","key":"2020021109364806300_B36","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","article-title":"Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"32","author":"Maurer","year":"2014","journal-title":"J Clin Oncol"},{"issue":"12","key":"2020021109364806300_B37","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","article-title":"Predictive biomarkers for checkpoint inhibitor-based immunotherapy","volume":"17","author":"Gibney","year":"2016","journal-title":"Lancet Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/133\/1\/81\/1551622\/blood865428.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/133\/1\/81\/1551622\/blood865428.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T10:33:43Z","timestamp":1581417223000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/133\/1\/81\/6619\/Genomic-alterations-important-for-the-prognosis-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,3]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1,3]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2018-07-865428","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,3]]}}}